AccScience Publishing / JCTR / Volume 2 / Issue 3 / DOI: 10.18053/jctres.02.201603.003
ORIGINAL ARTICLE

Hemoporfin-mediated photodynamic therapy on normal vasculature: implications for phototherapy of port-wine stain birthmarks

Wesley J Moy1,2 Gang Ma1,3 Kristen M Kelly1,4,5 Bernard Choi1,2,5,6,*
Show Less
1 Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA, United States
2 Department of Biomedical Engineering, University of California, Irvine, CA, Unites States
3 Department of Surgery, Shanghai Ninth People’s Hospital, Shanghai, China
4 Department of Dermatology, University of California, Irvine, CA, United States
5 Department of Surgery, University of California, Irvine, CA, United States
6 Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California, Irvine, CA, United States
Submitted: 8 July 2016 | Revised: 2 September 2016 | Accepted: 3 September 2016 | Published: 3 September 2016
© 2016 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Background: Port-wine stain (PWS) birthmarks currently are treated using a pulsed dye laser (PDL) combined with transient cooling of the epidermis. PDL treatment protocols utilize short pulses of light (585 or 595nm wavelength) to heat selectively the microvasculature due to absorption by intravascular hemoglobin. Although most patients respond to PDL therapy, few experience complete removal of the PWS. An alternate treatment option to PDL therapy of PWS is photodynamic therapy (PDT). Research groups have reported on various photosensitizers for PDT of PWS, including Hemoporfin, Benzoporphyrin Derivative monoacid ring A, and talaporfin sodium.


Aim: Our aim was to evaluate, with an established preclinical in-vivo model, the efficacy of photodynamic therapy (PDT) with Hemoporfin to achieve persistent vascular shutdown.


Methods: To monitor the microvasculature, a dorsal window chamber was surgically installed on 24 adult mice. The PDT excitation source emitted 150mW of 532nm light, with an irradiance of 100mW/cm2. A retroorbital injection of Hemoporfin (2 mg/kg) was performed to deliver the drug into the bloodstream. Laser irradiation was initiated immediately after injection. To monitor blood-flow dynamics in response to PDT, we used laser speckle imaging. We employed a dose–response experimental design to study the efficacy of Hemoporfin-mediated PDT to achieve persistent vascular shutdown observed on Day 7 after PDT.


Results: We observed four general hemodynamic responses to PDT: (1) At low radiant exposures, we did not observe any persistent vascular shutdown; (2) at intermediate radiant exposures, we observed delayed vascular shutdown effect with significant change to the vascular structure; (3) at intermediate radiant exposures, we observed an acute vascular shutdown effect with gradual restoration of blood flow and no significant changes to the vascular structure; and (4) at high radiant exposures, we observed acute vascular shutdown that persisted during the entire 7-day monitoring period, with no change in vascular structure. With light dose–response analysis, we estimated a characteristic radiant exposure of 359 J/cm2 that was required to achieve persistent vascular shutdown observed on Day 7 after PDT.


Conclusions: The experimental data collectively suggest that Hemoporfin-mediated PDT can achieve persistent vascular shutdown of normal microvasculature. However, compared with our previous data using Talaporfin Sodium as photosensitizer, Hemoporfin-mediated PDT is less efficient and requires a considerably longer (~four times) irradiation time. 


Relevance for patients: Patients with PWS lesions may benefit from the advantages that PDT potentially offers over conventional PDL therapy. PDT potentially is safer for patients of all skin types and more effective at treatment of recalcitrant lesions. Although clinical data suggest that Hemoporfin-mediated PDT is a promising alternative to PDL therapy, our results suggest that additional study of other photosensitizers is warranted. 

Keywords
photochemical
photothermal
talaporfin sodium
benzoporphyrin derivative monoacid ring A
skinfold
laser speckle contrast imaging
laser speckle contrast analysis
Conflict of interest
The authors declare they have no competing interests.
References

[1] Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976; 58: 218-222.

[2] Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: A review of 49 cases. Lasers in Surgery and Medicine 2007; 39: 563-568.

[3] Chen D, Hu XJ, Lin XX, Ma G, Jin YB, Chen H, Li W, Jiang CH. Nodules arising within port-wine stains: a clinicopatho logic study of 31 cases. Am J Dermatopathol 2011; 33: 144-151.

[4] Gu Y, Huang NY, Liang J, Pan YM, Liu FG. [Clinical study of 1949 cases of port wine stains treated with vascular photody namic therapy (Gu's pdt)]. Ann Dermatol Venereol 2007; 134: 241-244.

[5] Pu Y, Chen W, Yu Z. Research progress of Hemoporfin – part one: preclinical study. Photodiagnosis Photodyn Ther 2012; 9: 180-185.

[6] Xiao Q, Li Q, Yuan KH, Cheng B. Photodynamic therapy of port-wine stains: Long-term efficacy and complication in chi nese patients: Photodynamic therapy of port-wine stains. J Dermatol 2011; 38: 1146-1152.

[7] Channual J, Choi B, Osann K, Pattanachinda D, Lotfi J, Kelly KM. Vascular effects of photodynamic and pulsed dye laser therapy protocols. Lasers Surg Med 2008; 40: 644-650.

[8] Moy WJ, Patel SJ, Lertsakdadet BS, Arora RP, Nielsen KM, Kelly KM, Choi B. Preclinical in vivo evaluation of npe6-m-ediated photodynamic therapy on normal vasculature. Lasers Surg Med 2012; 44: 158-162.

[9] Smith TK, Choi B, Ramirez-San-Juan JC, Nelson JS, Osann K, Kelly KM. Microvascular blood flow dynamics associated with photodynamic therapy, pulsed dye laser irradiation and combined regimens. Lasers Surg Med 2006; 38: 532-539.

[10] Tournas JA, Lai J, Truitt A, Huang YC, Osann KE, Choi B, Kelly KM. Combined benzoporphyrin derivative monoacid ring photodynamic therapy and pulsed dye laser for port wine stain birthmarks. Photodiagnosis Photodyn Ther 2009; 6: 195- 199.

[11] Kelly KM, Moy WJ, Moy AJ, Lertsakdadet BS, Moy JJ, Ngu yen E, Nguyen A, Osann KE, Choi B. Talaporfin sodium- me diated photodynamic therapy alone and in combination with pulsed dye laser on cutaneous vasculature. J Invest Dermatol 2015; 135: 302-304.

[12] Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weis berger A, DENALI Study Group. Verteporfin plus ranibi zumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119: 1001-1010.

[13] Moy AJ, White SM, Indrawan ES, Lofti J, Nudelman MJ, Costantini SJ, Agarwal N, Jia W, Kelly KM, Sorg BS, Choi B. Wide-field functional imaging of blood flow and hemoglobin oxygen saturation in the rodent dorsal window chamber. Mi crovasc Res 2011; 82:199-209.

[14] Ramirez-San-Juan JC, Ramos-Garcia R, Guizar-Iturbide I, Martinez-Niconoff G, Choi B. Impact of velocity distribution assumption on simplified laser speckle imaging equation. Opt Express 200; 16: 3197-3203.

[15] Qin ZP, Li KL, Ren L, Liu XJ. Photodynamic therapy of port wine stains-a report of 238 cases. Photodiagnosis Photodyn Ther 2007; 4: 53-59.

[16] Zhao Y, Zhou Z, Zhou G, Tu P, Zheng Q, Tao J, Gu Y, Zhu X. Efficacy and safety of hemoporfin in photodynamic therapy for port-wine stain: a multicenter and open-labeled phase IIa study. Photodermatol Photoimmunol Photomed 2011; 27: 17- 23.

Share
Back to top
Journal of Clinical and Translational Research, Electronic ISSN: 2424-810X Print ISSN: 2382-6533, Published by AccScience Publishing